Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with Kawasaki disease
© Kemmotsu et al; licensee BioMed Central Ltd. 2011
Received: 20 May 2011
Accepted: 14 September 2011
Published: 14 September 2011
Aseptic meningitis is a serious adverse reaction to intravenous immunoglobulin (IVIG) therapy. We studied the clinical characteristics of patients with acute Kawasaki disease (KD) who developed IVIG-induced aseptic meningitis.
A retrospective analysis of the medical records of patients with KD who developed aseptic meningitis after IVIG treatment was performed.
During the 10-year period from 2000 through 2009, among a total of 384 patients with Kawasaki disease, 4 (3 females and 1 male; age range, 19-120 months) developed aseptic meningitis after IVIG. All 4 developed aseptic meningitis within 48 hours (range, 25-40 hours) of initiation of IVIG. The analyses of cerebrospinal fluid (CSF) revealed elevated white blood cell counts (22-1,248/μL) in all 4 patients; a predominance of polynuclear cells (65%-89%) was noted in 3. The CSF protein level was elevated in only 1 patient (59 mg/dL), and the glucose levels were normal in all 4 patients. Two patients were treated with intravenous methylprednisolone; the other 2 children were observed carefully without any special therapy. All patients recovered without neurological complications.
In our patients with Kawasaki disease, aseptic meningitis induced by IVIG occurred within 48 hours after initiation of IVIG, resolved within a few days, and resulted in no neurological complications, even in patients who did not receive medical treatment.
KeywordsKawasaki disease intravenous immunoglobulin aseptic meningitis
Intravenous immunoglobulin (IVIG) is a blood product that is widely used in the treatment of a number of medical conditions, including immunodeficiency disorders, inflammatory diseases, and autoimmune diseases.
Kawasaki disease (KD) is a self-limited systemic vasculitis syndrome of childhood that was first reported by Tomisaku Kawasaki in 1967 . Patients typically develop a fever, bulbar conjunctival injection, changes in the oropharyngeal mucosa and peripheral extremities, cervical lymphadenopathy, and a polymorphous rash. Coronary aneurysm and myocardial infarction are the most serious complications of this disease. In Japan, there are approximately 10,000 incident cases per year . The etiology of the disease is not well understood, but high-dose IVIG is known to prevent the coronary complications [3, 4].
There have been a number of reports regarding IVIG-induced adverse reactions, including mild reactions such as tachycardia, headache, facial flushing, nausea, diarrhea, and rash, as well as serious adverse reactions such as anaphylaxis, acute renal failure, and thromboembolic events . Aseptic meningitis is a neurologic adverse event that can be caused by IVIG. Although there have been case reports describing IVIG-induced aseptic meningitis, few studies have described the characteristics of a group of such patients. In this study, we describe the clinical and laboratory characteristics of IVIG-induced aseptic meningitis in 4 patients with KD.
Patients and methods
To investigate the clinical characteristics of IVIG-induced meningitis in KD patients, we retrospectively reviewed the medical records of patients who were admitted to our university hospital during the 10-year period from 2000 through 2009. All patients met the Japanese criteria for typical KD on admission. They were treated with oral aspirin and 1 or 2 g/kg of IVIG, the latter of which was administered over 12 or 24 hours, respectively. The IVIG products were freeze-dried sulfonated (Kenketsu Venilon®-I, Chemo-Sero-Therapeutic Research Institute, Kumamoto, Japan) and freeze-dried, polyethylene glycol (PEG) -treated (Kenketsu Glovenin®-I, Nihon Pharmaceutical Co, Ltd, Tokyo, Japan) human normal immunoglobulin. Testing of the CSF was done soon after the diagnosis of suspected IVIG-induced meningitis, and a diagnosis of meningitis was made on the basis of clinical symptoms such as fever and headache, meningeal irritation signs, and CSF pleocytosis. A final diagnosis of aseptic meningitis was made by negative bacterial culture results.
Characteristics of the study population and IVIG products
Background characteristics of the patients
IVIG product and dose
Day on IVIG
Clinical course and laboratory findings
The clinical course of the patients.
Time from start of IVIG to onset, hrs
Time to recovery
1 y male
15 mg/kg mPSL
6 y female
15 mg/kg mPSL
7 y female
10 y female
Cerebrospinal fluid findings
1 y male
1,248 (P 89%)
6 y female
120 (P 13%)
7 y female
648 (P 83%)
10 y female
21 (P 65%)
Aseptic meningitis after IVIG was first reported in 1988 . Since then, there have been similar case reports of IVIG-induced meningitis in patients with medical conditions such as idiopathic thrombocytopenic purpura (ITP), myasthenia gravis, and inflammatory demyelinating neuropathy [7–9]. There has previously been only 1 case report describing this complication in a patient with KD .
The rate of aseptic meningitis after IVIG was 1% (4 of 384) in this study, but the frequency varies widely, from 0% to 11%, in reports of patients with different underlying diseases [11, 12]. It was also reported that the development of aseptic meningitis was not correlated with the patient age or the type of underlying neuromuscular disease .
Hamrock reported that most patients who developed aseptic meningitis received 2 g/kg of IVIG, and that meningitis did not occur in any of their patients receiving a standard replacement dose of IVIG for a congenital immunodeficiency . All of our patients received high-dose IVIG at a dose of 1 or 2 g/kg. Our patients almost equally received sulfonated IVIG or PEG-treated IVIG, and 2 patients in each group (total 4) developed meningitis, thus indicating that there are no apparent differences in the effects of sulfaonated or PEG-treated IVIG with regard to the development of meningitis. In this study, patients were exposed to either sulfonated IVIG or PEG-treated IVIG, but not to products manufactured by other processes such as cold ethanol Cohn fractionation/ultrafiltration, ion exchange, or low-PH treatment. The inability to further explore the possible etiological factors related to specific IVIG brand or manufacturing lots may be a limitation of this study. There were no obvious differences of clinical and laboratory data, including the severity of KD on admission, day of initiating IVIG, or changes of inflammatory markers after IVIG between patients who developed meningitis and those who did not.
In the present study, aseptic meningitis developed within 25 to 40 hours after initiation of IVIG. In previous case reports, most patients also developed meningitis within 48 hours of beginning IVIG. Although all of our patients developed a fever and typical meningeal irritation signs, it may be possible that milder cases of aseptic meningitis could be misdiagnosed as IVIG- refractory KD, since the onset of fever after completion of IVIG therapy is often interpreted as recrudescence of KD. It is important to consider the possibility of IVIG-induced meningitis with careful physical examinations to avoid unnecessary therapies, such as additional IVIG, steroids, and infliximab.
CSF examinations revealed neutrophilic pleocytosis in 3 of our 4 patients, slight elevation of the protein level in 1 patient, and normal glucose levels in all 4 patients. These findings were similar to those of previous reports. The analysis of the CSF in patients with aseptic meningitis usually shows pleocytosis with neutrophil predominance, normal or slightly elevated protein, and normal glucose levels. It may therefore be difficult to differentiate IVIG-induced meningitis from viral meningitis by the CSF findings, as it has been reported that the CSF protein levels are normal to mildly elevated, glucose levels are normal to slightly depressed, and neutrophil predominance is also seen in pediatric patients with viral meningitis [13, 14].
All of our patients recovered without developing any neurological complications. Two were treated with intravenous methylprednisolone, and the other 2 were monitored without medical treatment. Jayabose et al. reported that children with ITP who were given prednisone had a lower risk of neurological complications after IVIG . However, it has also been reported that such symptoms are self-limiting, and that there is no specific therapy that shortens the duration of symptoms. Thus, it may be advisable to carefully observe such patients and avoid systemic therapy . In our study, there were no obvious differences in the clinical courses between patients treated with intravenous methylprednisolone and those who received no medical treatment, which suggests that systemic steroid administration is not beneficial for IVIG-induced meningitis.
The mechanisms underlying IVIG-induced meningitis are not clear. One possible cause is an allergic hypersensitivity reaction caused by direct entry of the IVIG preparation into the CSF compartment. This is supported by the fact that CSF eosinophilia has been observed in some patients . In our study, one patient exhibited peripheral eosinophilia (11% of the total 5,800/μL white blood cells) but CSF eosinophilia was not observed in any of our patients. None of our patients developed exanthema after IVIG. Although our patients received no pre-treatment, it may be useful to give antihistamines prior to IVIG if allergic reaction is one of the mechanisms responsible for IVIG-induced meningitis. Recently, it was reported that there were increased levels of CSF monocyte chemoattractant protein-1 (MCP-1) in ITP patients with IVIG-induced meningitis, which suggests a role for monocytes in the inflammation of the meninges . On the other hand, Jarius et al. reported that aseptic meningitis was frequently associated with neutrophillic pleocytosis in the CSF and in vivo activation of TNF-α-primed neutrophils by atypical antineutrophil cytoplasmic antibodies in IVIG might contribute to aseptic meningitis . In our present study, the CSF cytokines or chemokines were not measured.
A comparison between IVIG- and KD-induced meningitis
Meningitis due to IVIG
Meningitis due to KD
Within 48 hrs after IVIG
Early in the stage, before IVIG
Typical meningeal signs
Can lack meningeal signs
Polynuclear cell predominance
Mononuclear cell predominance
No special therapy
Therapy for KD
In conclusion, IVIG-induced meningitis developed within 48 hours of initiating IVIG and resolved in a few days, without neurological complications, and systemic steroid administration was not beneficial in our patients. Further investigations of the pathophysiology of IVIG-induced meningitis, including a detailed analysis of the underlying mechanisms, are needed.
- Kawasaki T: Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi. 1967, 16 (3): 178-222.PubMed
- Nakamura Y, Yashiro M, Uehara R, Oki I, Watanabe M, Yanagawa H: Epidemiologic Features of Kawasaki Disease in Japan: Results from the Nationwide Survey in 2005-2006. J Epidemiol. 2008, 18: 167-172. 10.2188/jea.JE2008001.View ArticlePubMed
- Newburger JW, Takahashi M, Burns JC: The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986, 315: 341-347. 10.1056/NEJM198608073150601.View ArticlePubMed
- Newburger JW, Takahashi M, Beiser AS: A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991, 324: 1633-1639. 10.1056/NEJM199106063242305.View ArticlePubMed
- Hamrock DJ: Adverse events associated with intravenous immunoglobulin therapy. Intl Immunopharmacol. 2006, 6: 535-542. 10.1016/j.intimp.2005.11.015.View Article
- Kato E, Shindo S, Eto Y, Hashimoto N, Yamamoto M, Sakata Y: Administration of immune globulin associated with aseptic meningitis. JAMA. 1988, 259: 3269-3271.View ArticlePubMed
- Jayabose S, Roseman B, Gupta A: Aseptic meningitis syndrome (AMS) after IV gammaglobulin (I.V. Gg) therapy for ITP. Am J Pediatr Hematolo Oncol. 1990, 12: 117-
- Meiner Z, Ben-Hur T, River Y, Reches A: Aseptic meningitis as complication of intravenous immunoglobulin therapy for myasthenia gravis. J Neurol Neurosurg Psychiatry. 1993, 56: 830-831.PubMed CentralView ArticlePubMed
- Vera-Ramirez M, Charlet M, Parry GJ: Recurrent aseptic meningitis complicating intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 1992, 42: 1636-1637.View ArticlePubMed
- Boyce TG, Spearman P: Acute aseptic meningitis secondary to intravenous immunoglobulin in a patient with Kawasaki syndrome. Pediatr Infect Dis J. 1998, 17: 1054-1056. 10.1097/00006454-199811000-00023.View ArticlePubMed
- Orbach H, Katz U, Sherer Y, Shoenfeld Y: Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol. 2005, 29: 173-184. 10.1385/CRIAI:29:3:173.View ArticlePubMed
- Sekul EA, Cupler EJ, Dalakas MC: Aseptic Meningitis Associated with High-Dose Intravenous Immunoglobulin Therapy: Frequency and Risk Factors. Ann Intern Med. 1994, 121: 259-262.View ArticlePubMed
- Irani DN: Aseptic Meningitis and Viral Myelitis. Neurol Clin. 2008, 26 (3): 635-655. 10.1016/j.ncl.2008.03.003.PubMed CentralView ArticlePubMed
- Negrini B, Kelleher KJ, Wald ER: Cerebrospinal fluid findings in aseptic versus bacterial meningitis. Pediatrics. 2000, 105 (2): 316-319. 10.1542/peds.105.2.316.View ArticlePubMed
- Jayabose S, Mahmoud M, Levendoglu-Tuga O: Corticosteroid prophylaxis for neurologic complications of intravenous immunoglobulin G therapy in childhood immune thrombocytopenic purpura. J Pediatr Hematol Oncol. 1999, 21: 514-517. 10.1097/00043426-199911000-00012.View ArticlePubMed
- Asano T, Koizumi S, Mishina-Ikegami K, Hatori T, Miyasho T, Fujino O: Increased levels of Monocyte Chemoattractant Protein-1 in cerebrospinal fluid with gamma globulin induced meningitis. Acta Paediatr. 2010, 99: 164-165.PubMed
- Jarius S, Eichhorn P, Albert MH, Wagenpfeil S, Wick M, Belohradsky BH, Hohlfeld R, Jenne DE, Voltz R: Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNFα-dependent and Fc-receptor-independent way. Blood. 2007, 109: 4376-4382. 10.1182/blood-2005-12-019604.View ArticlePubMed
- Dengler LD, Capparelli EV, Bastian JF, Bradley DJ, Glode MP, Santa S, Newburger JW, Baker AL, Matsubara T, Burns JC: Cerebrospinal fluid profile in patients with acute Kawasaki disease. Pediatr Infect Dis J. 1998, 17: 478-481. 10.1097/00006454-199806000-00008.View ArticlePubMed
- Takagi K, Umezawa T, Saji T, Morooka K, Matsuo N: Meningoencephalitis in Kawasaki disease. No To Hattatsu (in Japanese). 1990, 22: 429-435.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.